Virus-Inactivated Cell Composition for Allogeneic Tissue Repair

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing therapeutic methods for tissue repair, particularly using allogeneic stem cells, face challenges such as immune response, rejection, and the risk of viral transmission, while autologous cell use is inconvenient and costly.

Innovation Solution

Development of sterilized and virus-inactivated compositions comprising multipotent cells or microvascular tissue, which are not cultured and can be stored at room temperature, offering angiogenic and anti-inflammatory properties for allogeneic or xenogeneic use.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If allogeneic stem cells are used for tissue repair, then treatment effectiveness is improved, but immune response and rejection risk increase

Engineering Contradiction:

Improvetissue repair effectivenessVSAvoidimmune response and rejection

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent extracts and removes cellular components that trigger immune responses while retaining therapeutic benefits. Specifically, the composition is treated to remove nucleic acids and other immunogenic elements, leaving behind therapeutic factors that promote tissue repair without causing rejection

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The patent converts potentially harmful allogeneic cells into beneficial therapeutic compositions by treating them to eliminate immunogenicity. The treated composition maintains tissue repair capabilities while the harmful immune-triggering properties are transformed into safe, non-rejectable therapeutic agents

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

2Object-affected harmful factors

If autologous stem cells are used for tissue repair, then immune rejection is avoided, but treatment convenience and cost worsen

Engineering Contradiction:

Improveimmune rejection riskVSAvoidtreatment convenience

Core Design Contradiction:

Object-affected harmful factorsVSEase of operation

Solution Approach 1:

The patent performs preliminary treatment of allogeneic stem cells to create a universal, pre-screened composition that can be stored and used immediately. This preliminary processing eliminates the need for individual patient cell harvesting and processing, making treatment as convenient as autologous approaches but without the logistical burden

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The patent creates a standardized, pre-treated composition that serves as a universal template for tissue repair. Instead of creating custom treatments for each patient, a single pre-treated composition type can be used across multiple patients, significantly simplifying the treatment process while maintaining safety

Inventive Principle:

Principle #26Copying

3Productivity

If allogeneic stem cells are used for tissue repair, then treatment availability is improved, but viral transmission risk increases

Engineering Contradiction:

Improvetreatment availabilityVSAvoidviral transmission risk

Core Design Contradiction:

ProductivityVSObject-generated harmful factors

Solution Approach 1:

The patent removes viral contaminants and immunogenic cellular components from the allogeneic stem cell composition through treatment processes. This extraction eliminates viral transmission risks while preserving the therapeutic capabilities of the composition

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The patent treats the allogeneic stem cells to create a single-use, disposable composition that has been pre-screened and treated for safety. Each composition is independently treated and can be used immediately without further processing, ensuring viral safety while maintaining treatment availability

Inventive Principle:

Principle #27Cheap short-living objects (Disposable)

Data Source

PatentUS20250367241A1Compositions and methods for treating and preventing tissue injury and disease

Publication Date: 2025.12.04 MICROVASCULAR TISSUES INC

AI summary

The present invention provides novel compositions comprising multipotent cells or microvascular tissue, wherein the cells or tissue has been sterilized and/or treated to inactivated viruses, and related methods of using these compositions to treat or prevent tissue injury or disease in an allogeneic subject.